One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Considerations in association studies in dermatoepidemiology
T. Nijsten, J. Silverberg, P. Gisondi, C. Vestergaard, L. Hollestein, M. Wakkee
doi : 10.1111/bjd.20393
Volume185, Issue1,Pages 1-2
Only the best instruments should be used to measure core outcomes
J. Kottner, J. Schmitt
doi : 10.1111/bjd.19836
Volume185, Issue1,Pages 3-4
The development and use of Core Outcome Sets (COS) is increasingly recognized as an important aspect to improve the quality and usefulness of clinical trial evidence. In dermatology, several COS have been published or are under development.1 The Cochrane Skin-Core Outcome Set Initiative (CS-COUSIN, http://cs-cousin.org/) supports the development of COS in dermatology and offers guidance and support for COS development groups. Currently, 21 COS groups are affiliated with CS-COUSIN, among them the Acne Core Outcomes Research Network (ACORN). In COS development, the selection and prioritization of critical outcome domains is a crucial first step which is followed by the selection of outcome measurement instruments (OMIs) per domain. Guidance on how to best select core outcome domains is available to support this complex and challenging process.2 However, the appropriate selection of OMIs is at least as challenging as selecting core domains.3
Silicone adhesive multilayered foam dressings for pressure ulcer prevention
F. Coyer
doi : 10.1111/bjd.19873
Volume185, Issue1,Pages 4-5
no abstract
Fumaric acid esters for paediatric psoriasis
B. Volc-Platzer
doi : 10.1111/bjd.20057
Volume185, Issue1,Pages 5-6
Elevated body mass index, a risk factor or consequence of hidradenitis suppurativa?
L.A.V. Orenstein
doi : 10.1111/bjd.19886
Volume185, Issue1,Pages 6-7
Psoriasis, COVID-19 and shielding
G. Becher, A.D. Burden
doi : 10.1111/bjd.20055
Volume185, Issue1,Pages 7-8
The COVID-19 pandemic has presented clinicians managing immune-mediated inflammatory diseases (IMIDs) such as psoriasis, with many challenges. Patients with severe psoriasis have an increased prevalence of risk factors for severe COVID-19 including obesity, hypertension, diabetes and male sex.1 Moreover, many systemic treatments for psoriasis are known to increase the risk of severe infection. Therefore, it is understandable that in the early stages of the pandemic, patients on conventional targeted systemic therapies were considered to be at higher risk of severe COVID-19 infection. In addition to risk-mitigating behaviours such as social distancing recommended by the World Health Organization, those who were thought to be more vulnerable, for instance those on immunosuppressants, were advised to adopt stricter measures of social isolation including distancing themselves from other members of their household.2, 3 There was a pressing need to establish whether patients on immunosuppressive or immunomodulatory medications should continue on their medications.
Psychiatric conditions in children with atopic dermatitis
E.K. Johansson
doi : 10.1111/bjd.20394
Volume185, Issue1,Pages 8-9
It is well-known that children with atopic dermatitis (AD) have a reduced health-related quality of life that is of a similar magnitude to children with cerebral palsy and diabetes mellitus.1, 2 It is also known that children with AD have an increased risk of attention deficit hyperactivity disorder (ADHD).3 Less is known about other psychiatric comorbidities in children with AD.
Melanoma origins: data from early-stage tumours supports de novo and naevus-associated melanomas as distinct subtypes
J. Wiggins, D. Polsky
doi : 10.1111/bjd.20396
Volume185, Issue1,Pages 9-10
Cellulitis in chronic oedema
P. S. Mortimer
doi : 10.1111/bjd.20047
Volume185, Issue1,Pages 10-11
Cellulitis (also known as erysipelas) is a common infection of the skin and subcutaneous tissues, and therefore falls within the domain of dermatologists. Cellulitis, which can often be recurrent, is among the top 10 reasons for admission to hospital, with patients receiving treatment from many specialties including emergency care, general practitioners, general medicine, surgery, tissue viability and dermatology.1
Using epidemiological methods to quantify the risk of serious infections in children with atopic dermatitis
M. Linder
doi : 10.1111/bjd.20395
Volume185, Issue1,Pages 11-12
In their article in this issue, Droitcourt et al. investigate the risk of some systemic infections leading to hospitalization in children with atopic dermatitis (AD) compared with sex- and age-matched comparators in Denmark.1 Studied outcomes were upper and lower respiratory tract, gastrointestinal tract, musculoskeletal tract, urinary tract, heart and central nervous system infections and sepsis. Infections treated in hospitals were regarded as serious infections, and AD was defined as at least one recorded diagnosis of AD, but an algorithm may have captured more children with AD.2
How stress affects the skin: from designs to mechanisms
A.W.M. Evers, S. van Beugen
doi : 10.1111/bjd.20397
Volume185, Issue1,Pages 12-13
The reciprocal relationship between stress and skin diseases is well known, showing that for example many chronic skin diseases induce moderate-to-severe stress responses,1, 2 such as subjective levels of psychological distress and a physiological stress response of altered hypothalamic–pituitary–adrenal (HPA) axis activity, that in turn might trigger a worsened disease course or progression.3 Although there is considerable evidence showing that stress is a common psychological consequence of skin conditions,1 there is much less ‘hardcore’ evidence from prospective studies about the possible causal effects of stress on the origin or course of a skin disease.4 There are at least three ways through which stress can affect the skin that all ask for different designs.
What instruments should we add to our toolbox for measuring the severity and control of eczema?
D.F. Murrell, C.F. Paul
doi : 10.1111/bjd.20398
Volume185, Issue1,Pages 13-14
Ceramide kinase-like protein, ‘the kinase that isn’t’, finds a role in skin cancer stress relief
R.F.L. O’Shaughnessy
doi : 10.1111/bjd.19888
Volume185, Issue1,Pages 14-15
Neutrophil trafficking: the missing link in the pathogenesis of hidradenitis suppurativa
E.J. Giamarellos-Bourboulis
doi : 10.1111/bjd.20086
Volume185, Issue1,Pages 15-16
Biologic survival in hidradenitis suppurativa: much done, more to do
R. Hambly, B. Kirby
doi : 10.1111/bjd.20399
Volume185, Issue1,Pages 16-17
Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease, with multiple systemic comorbidities1 Treatment is challenging and adalimumab [tumour necrosis factor (TNF)-? monoclonal antibody] is the only licensed therapy. It is effective in approximately 50% of patients, based on Hidradenitis Suppurativa Clinical Response results from the phase III trials PIONEER I and II.2
Hand eczema in young people: atopic dermatitis and beyond
A. Schnuch
doi : 10.1111/bjd.20142
Volume185, Issue1,Pages 17-18
The importance of assessing blood tumour burden in cutaneous T-cell lymphoma*
M.H. Vermeer, J.P. Nicolay, J.J. Scarisbrick, P.L. Zinzani
doi : 10.1111/bjd.19669
Volume185, Issue1,Pages 19-25
Tape strips in dermatology research*
A. J. Hughes, S. S. Tawfik, K. P. Baruah, E. A. O’Toole, R. F. L. O’Shaughnessy
doi : 10.1111/bjd.19760
Volume185, Issue1,Pages 26-35
Identifying and appraising patient-reported outcome measures on treatment satisfaction in acne: a systematic review*
E.J. van Zuuren, B.W.M. Arents, M. Miklas, J.W. Schoones, J. Tan
doi : 10.1111/bjd.19675
Volume185, Issue1,Pages 36-51
After dermatitis, acne is the next skin disease to contribute most to the burden of skin diseases worldwide. Recently, seven core outcome domains have been identified, which together form an Acne Core Outcome Set (ACORN). One of these was satisfaction with acne treatment.
Silicone adhesive multilayer foam dressings as adjuvant prophylactic therapy to prevent hospital-acquired pressure ulcers: a pragmatic noncommercial multicentre randomized open-label parallel-group medical device trial*
D. Beeckman, A. Fourie, C. Raepsaet, N. Van Damme, B. Manderlier, D. De Meyer, H. Beele, S. Smet, L. Demarré, R. Vossaert, A. de Graaf, L. Verhaeghe, N. Vandergheynst, B. Hendrickx, V. Hanssens, H. Keymeulen, K. Vanderwee, J. Van De Woestijne, S. Verhaeghe, A. Van Hecke, I. Savoye, J. Harrison, F. Vrijens, F. Hulstaert
doi : 10.1111/bjd.19689
Volume185, Issue1,Pages 52-61
Efficacy and safety of fumaric acid esters in young patients aged 10–17 years with moderate-to-severe plaque psoriasis: a randomized, double-blinded, placebo-controlled trial*
H. Hamm, D. Wilsmann-Theis, A. Tsianakas, T. Gambichler, K. Taipale, J. Lauterbach, U. Freudensprung, C. Makepeace, the KIFUderm study investigators
doi : 10.1111/bjd.19747
Volume185, Issue1,Pages 62-73
Trends in body mass index before and after diagnosis of hidradenitis suppurativa
S. Wright, A. Strunk, A. Garg
doi : 10.1111/bjd.19713
Volume185, Issue1,Pages 74-79
Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey*
S.K. Mahil, M. Yates, S.M. Langan, Z.Z.N. Yiu, T. Tsakok, N. Dand, K.J. Mason, H. McAteer, F. Meynell, B. Coker, A. Vincent, D. Urmston, A. Vesty, J. Kelly, C. Lancelot, L. Moorhead, H. Bachelez, I.N. Bruce, F. Capon, C.R. Contreras, A.P. Cope, C. De La Cruz, P. Di Meglio, P. Gisondi, K. Hyrich, D. Jullien, J. Lambert, H. Marzo-Ortega, I. McInnes, L. Naldi, S. Norton, L. Puig, R. Sengupta, P. Spuls, T. Torres, R.B. Warren, H. Waweru, J. Weinman, C.E.M. Griffiths, J.N. Barker, M.A. Brown, J.B. Galloway, C.H. Smith, on behalf of the PsoProtect, CORE-UK study groups
doi : 10.1111/bjd.19755
Volume185, Issue1,Pages 80-90
Association between hospital-diagnosed atopic dermatitis and psychiatric disorders and medication use in childhood*
I. Vittrup, Y. M. F. Andersen, C. Droitcourt, L. Skov, A. Egeberg, M. C. Fenton, P. Mina-Osorio, S. Boklage, J. P. Thyssen
doi : 10.1111/bjd.19817
Volume185, Issue1,Pages 91-100
A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences*
C. Dessinioti, A.C. Geller, A. Stergiopoulou, N. Dimou, S. Lo, U. Keim, J.E. Gershenwald, L.E. Haydu, R. Dummer, J. Mangana, A. Hauschild, F. Egberts, R. Vieira, A. Brinca, I. Zalaudek, T. Deinlein, E. Evangelou, J.F. Thompson, R.A. Scolyer, K. Peris, C. Garbe, A.J. Stratigos
doi : 10.1111/bjd.19819
Volume185, Issue1,Pages 101-109
Cellulitis in chronic oedema of the lower leg: an international cross-sectional study
E.A. Burian, T. Karlsmark, P.J. Franks, V. Keeley, I. Quéré, C.J. Moffatt
doi : 10.1111/bjd.19803
Volume185, Issue1,Pages 110-118
Risk of systemic infections requiring hospitalization in children with atopic dermatitis: a Danish retrospective nationwide cohort study*
C. Droitcourt, I. Vittrup, A. Dupuy, A. Egeberg, J.P. Thyssen
doi : 10.1111/bjd.19825
Volume185, Issue1,Pages 119-129
Perceived psychological stress and risk of herpes zoster: a nationwide population-based cohort study*
S.A.J. Schmidt, H.T. S?rensen, S.M. Langan, M. Vestergaard
doi : 10.1111/bjd.19832
Volume185, Issue1,Pages 130-138
Recommended core outcome instruments for health-related quality of life, long-term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*
K.S. Thomas, C.A. Apfelbacher, J.R. Chalmers, E. Simpson, P.I. Spuls, L.A.A. Gerbens, H.C. Williams, J. Schmitt, M. Gabes, L. Howells, B.L. Stuart, E. Grinich, T. Pawlitschek, T. Burton, L. Howie, A. Gadkari, L. Eckert, T. Ebata, M. Boers, H. Saeki, T. Nakahara, N. Katoh
doi : 10.1111/bjd.19751
Volume185, Issue1,Pages 139-146
CERKL is upregulated in cutaneous squamous cell carcinoma and maintains cellular sphingolipids and resistance to oxidative stress*
J.M. Meyer, E. Lee, A. Celli, K. Park, R. Cho, W. Lambert, M. Pitchford, M. Gordon, K. Tsai, J. Cleaver, S.T. Arron, T.M. Mauro
doi : 10.1111/bjd.19753
Volume185, Issue1,Pages 147-152
Topical corticosteroids normalize both skin and systemic inflammatory markers in infant atopic dermatitis
M. A. McAleer, I. Jakasa, N. Stefanovic, W. H. I. McLean, S. Kezic, A. D. Irvine
doi : 10.1111/bjd.19703
Volume185, Issue1,Pages 153-163
Activity and components of the granulocyte colony-stimulating factor pathway in hidradenitis suppurativa*
K. Wolk, T.-C. Brembach, D. ?imait?, E. Bartnik, S. Cucinotta, A. Pokrywka, M.L. Irmer, J. Triebus, E. Witte-H?ndel, G. Salinas, T. Leeuw, H.-D. Volk, K. Ghoreschi, R. Sabat
doi : 10.1111/bjd.19795
Volume185, Issue1,Pages 164-176
Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study*
L.M. Prens, K. Bouwman, P. Aarts, S. Arends, K.R. van Straalen, K. Dudink, B. Horv?th, E.P. Prens
doi : 10.1111/bjd.19863
Volume185, Issue1,Pages 177-184
Hand eczema in children referred for patch testing: North American Contact Dermatitis Group Data, 2000–2016*
J.I. Silverberg, E.M. Warshaw, H.I. Maibach, J.G. DeKoven, J.S. Taylor, A.R. Atwater, D. Sasseville, K.A. Zug, M.J. Reeder, J.F. Fowler Jr., M.D. Pratt, A.F. Fransway, M.J. Zirwas, D.V. Belsito, J.G. Marks Jr, V.A. DeLeo
doi : 10.1111/bjd.19818
Volume185, Issue1,Pages 185-194
Psoriasis: an example of the complexity of decision making
C. Bergqvist, R.S. Stern, O. Chosidow
doi : 10.1111/bjd.19715
Volume185, Issue1,Pages 195-197
Equity in skin typing: why it is time to replace the Fitzpatrick scale
U.K. Okoji, S.C. Taylor, J.B. Lipoff
doi : 10.1111/bjd.19932
Volume185, Issue1,Pages 198-199
Trends in opioid prescribing at outpatient visits for psoriasis and psoriatic arthritis
M.T. Taylor, M.H. Noe, D.B. Horton, J.S. Barbieri
doi : 10.1111/bjd.19865
Volume185, Issue1,Pages 200-201
The use of hydroxychloroquine as a systemic treatment in erosive lichen planus of the vulva and vagina
H. A. B. Vermeer, H. Rashid, M. D. Esajas, J. M. Oldhoff, B. Horv?th
doi : 10.1111/bjd.19870
Volume185, Issue1,Pages 201-203
Priority research questions in atopic dermatitis: an International Eczema Council eDelphi consensus
K. Abuabara, S.G. Nicholls, S.M. Langan, E. Guttman-Yassky, N.J. Reynolds, A.S. Paller, S.J. Brown, the International Eczema Council Priority Research Group
doi : 10.1111/bjd.19874
Volume185, Issue1,Pages 203-205
Ultraviolet-related skin cancers distribute differently on the face surface
T. Omodaka, A. Minagawa, R. Okuyama
doi : 10.1111/bjd.19875
Volume185, Issue1,Pages 205-207
Biologics utilization for psoriasis is lower in black compared with white patients
W.T. Hodges, T. Bhat, N.S. Raval, C. Herbosa, P. Ugwu-Dike, S.G. Kwatra, A. Musiek, C. Mann, Y.R. Semenov
doi : 10.1111/bjd.19876
Volume185, Issue1,Pages 207-209
COVID-19 vaccination intention among patients with psoriasis compared with immunosuppressed patients with other skin diseases and factors influencing their decision
E. Sotiriou, K. Bakirtzi, I. Papadimitriou, E. Paschou, E. Vakirlis, A. Lallas, D. Ioannides
doi : 10.1111/bjd.19882
Volume185, Issue1,Pages 209-210
Mortality and clinical response of patients with bullous pemphigoid treated with rituximab
D. S. Yoo, J. H. Lee, S. -C. Kim, J. H. Kim
doi : 10.1111/bjd.19890
Volume185, Issue1,Pages 210-212
Identifying gaps in global health dermatology: a survey of GLODERM members
D.E. McMahon, L. Oyesiku, E. Amerson, H. Beltraminelli, A.Y. Chang, A. Forrestel, R. Hay, A. Knapp, C. Kovarik, T. Maurer, S.A. Norton, W. Rehmus, C. Van Hees, K.A. Wanat, V.L. Williams, L.C. Fuller, E.E. Freeman
doi : 10.1111/bjd.19889
Volume185, Issue1,Pages 212-214
Cold and COVID: recurrent pernio during the COVID-19 pandemic
E.E. Freeman, D.E. McMahon, J.B. Lipoff, M. Rosenbach, S.R. Desai, M. Fassett, L.E. French, H.W. Lim, G.J. Hruza, L.P. Fox
doi : 10.1111/bjd.19894
Volume185, Issue1,Pages 214-216
Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa–acne inversa in patients of paediatric age: a pilot prospective study
V. Bettoli, G. Toni, G. Odorici, R. Forconi, M. Corazza
doi : 10.1111/bjd.19867
Volume185, Issue1,Pages 216-217
The less-known face of dupilumab: its role in mesenchymal stem cells by interleukin-13 modulation
A. Campanati, M. Di Vincenzo, G. Radi, G. Rizzetto, G. Carnevale, S. Marchi, M. Orciani, A. Offidani
doi : 10.1111/bjd.19892
Volume185, Issue1,Pages 217-219
Longitudinal multicentre retrospective cohort study of treatment outcomes in extramammary Paget disease
K.X. Liu, V. Huang, C.A. Chen, C.P. Elco, S.T. Chen, R.S. Stern, P.A. Wu
doi : 10.1111/bjd.19871
Volume185, Issue1,Pages 219-221
Exploring the melanoma survivorship experience: a qualitative study
Z.J. Wolner, N.I. Flowers, M.L. Yushak, S.C. Chen, H. Yeung
doi : 10.1111/bjd.19868
Volume185, Issue1,Pages 221-223
Current prevalence and relevance of positive patch test reactions to cosmetic and noncosmetic isothiazolinones in the UK
L.F. Soriano, M.M.U. Chowdhury, S.M. Cooper, P. Cousen, S. Dawe, A. Havelin, C.R. Holden, G.A. Johnston, D.I. Orton, A. Ramoutar, N.M. Stone, D.A. Thompson, D.A. Buckley
doi : 10.1111/bjd.19898
Volume185, Issue1,Pages 223-225
Identifying triggers for hidradenitis suppurativa flare: a patient survey
A.M. Thompson, J.M. Fernandez, J. Rick, A.J. Hendricks, M. Maarouf, E.M. Mata, E.K. Collier, T.R. Grogan, J.L. Hsiao, V.Y. Shi
doi : 10.1111/bjd.19926
Volume185, Issue1,Pages 225-226
Recurrence of chilblains during a second contact with SARS-CoV-2: a case report
S. Maanaoui, F. Salez, O. Carpentier
doi : 10.1111/bjd.20070
Volume185, Issue1,Pages 227-228
Most rare subtypes of cutaneous lymphoma display variable CD30 expression: analysis of the German Cutaneous Lymphoma Network
U. Wehkamp, C. Mitteldorf, S. Stendel, R. Stranzenbach, J.P. Nicolay, M. Wobser, M. Weichenthal, R. Schneiderbauer, C.-D. Klemke, U. Hillen, W. Kempf, C. Assaf
doi : 10.1111/bjd.19823
Volume185, Issue1,Pages 228-230
Journal attitudes and outcomes of preprints in dermatology
J.L. Jia, V.J. Hua, D.E. Mills, K.Y. Sarin
doi : 10.1111/bjd.20065
Volume185, Issue1,Pages 230-232
Skin-associated lymphoid tissue could be a sign of systemic disease
C. Wang
doi : 10.1111/bjd.19881
Volume185, Issue1,Pages 233-233
Skin-associated lymphoid tissue could be a sign of systemic disease: reply from authors
T. Kogame, N. Kambe, R. Takimoto-Ito, T. Nomura, K. Kabashima
doi : 10.1111/bjd.19884
Volume185, Issue1,Pages 233-234
Actinic keratoses: pain severity after cryotherapy and patient tolerability of treatment
G. Quinn, C. MacEochagain, J. Mac Mahon, L. Killion, N. Ralph, P. Lenane, A. Murad, I. McDonald, F.J. Moloney
doi : 10.1111/bjd.19869
Volume185, Issue1,Pages 234-235
Response to: ‘Successful treatment of refractory extensive pityriasis rubra pilaris with risankizumab’
B. Duarte, M.J. Paiva Lopes
doi : 10.1111/bjd.20061
Volume185, Issue1,Pages 235-236
Professor Lionel Fry (1933–2021)
C.E.M. Griffiths
doi : 10.1111/bjd.20075
Volume185, Issue1,Pages 237-238
Foreign body cystic granuloma and abscess after acupoint catgut embedding
Y.H. Wang, W.T. Chen
doi : 10.1111/bjd.20056
Volume185, Issue1,Pages e1-e1
Paradoxical worsening of pemphigus after rituximab presenting as figurate bullous eruption
H. Mahmoudi, A. Nili, A. Salehi Farid, S. Tavakolpour, M. Daneshpazhooh
doi : 10.1111/bjd.20054
Volume185, Issue1,Pages e2-e2
Chilblain lesions after COVID-19 mRNA vaccine
A. Pileri, A. Guglielmo, B. Raone, A. Patrizi
doi : 10.1111/bjd.20060
Volume185, Issue1,Pages e3-e3
Ceramide kinase-like protein promotes cutaneous squamous cell carcinoma
doi : 10.1111/bjd.20442
Volume185, Issue1,Pages e4-e4
Does psychological stress increase the risk of herpes zoster (shingles)?
doi : 10.1111/bjd.20443
Volume185, Issue1,Pages e5-e5
Zoster (shingles) is a painful skin disease caused by the same virus that is responsible for chickenpox (varicella). After chickenpox infection, the virus rests in the nerves of the body; but later in life it may become activated and then zoster develops. This occurs in roughly one-third of the population during their lifetime and it can be triggered by a weakened immune system. Because psychological stress can have a negative impact on the immune system, it has been suggested that it can lead to zoster.
How is patient satisfaction with acne treatment measured?
doi : 10.1111/bjd.20444
Volume185, Issue1,Pages e6-e6
Acne is a common skin disease that causes a lot of burden and distress. Acne can be treated with medication applied to the skin (e.g. creams) and with oral medication (e.g. tablets). It is important to know how satisfied people with acne actually are with their treatment. So this should be measured in studies that evaluate acne treatments.
Tablets containing fumaric acid esters lead to improvement of psoriasis in children and adolescents
doi : 10.1111/bjd.20445
Volume185, Issue1,Pages e7-e7
Psoriasis is an inflammatory skin disease that can begin during childhood. In Germany, psoriasis affects seven out of 1000 children and adolescents. The condition in these young people is challenging to treat because many drugs are only approved for adults. Tablets containing fumaric acid esters are successfully used to treat adults with psoriasis. This study from Germany aimed to find out if fumaric acid esters can also improve psoriasis in children and adolescents.
Are children with atopic eczema more likely than other children to develop serious internal infections?
doi : 10.1111/bjd.20446
Volume185, Issue1,Pages e8-e8
As a background to this study it is known that children with atopic dermatitis (AD) have an increased risk of developing skin infections caused by bacteria such as Staphylococcus aureus as well as viruses including herpes simplex. This then raises the question as to whether children with AD are, in addition, at greater risk from internal infections.
Assessing the blood in T-cell lymphoma of the skin
doi : 10.1111/bjd.20447
Volume185, Issue1,Pages e9-e9
A lymphoma is a cancer of lymphocytes, cells that form part of the immune system. One type of lymphocyte that can become cancerous is the T-lymphocyte, or ‘T-cell’. Cutaneous T-cell lymphoma (CTCL) is a form of lymphoma that originates in the skin, and the two subtypes we know most about are mycosis fungoides (MF) and Sézary syndrome (SS). MF is the commonest sub-type whereas SS is much rarer. One criterion for diagnosing SS is finding significant numbers of abnormal lymphocytes in the bloodstream, as in leukaemia. Most patients with MF do not have this finding, but the outlook is worse if they do.
Special dressings as an additional strategy to prevent pressure ulcers in hospital
doi : 10.1111/bjd.20448
Volume185, Issue1,Pages e10-e10
Immobility is one of the factors contributing to why patients develop pressure-related wounds. Even though hospitals use strategies such as turning patients every 2–4 h, some patients still get these ulcers (also known as pressure sores), which can be painful and expensive to treat. A recent summary of studies showed that on average, 13 out of 100 patients develop pressure ulcers and 50% of these wounds are on the buttock area.
HOME VII consensus decisions for measuring eczema control, quality of life and itch intensity
doi : 10.1111/bjd.20449
Volume185, Issue1,Pages e11-e11
The Harmonising Outcome Measures for Eczema (HOME) initiative is an international collaboration involving people with eczema, health professionals, researchers, regulators and industry representatives. The collaboration is working globally to agree a defined list of aspects of eczema that should be measured in all future eczema clinical trials and systematic reviews.
Melanoma arising on a naevus is different from melanoma arising de novo
doi : 10.1111/bjd.20450
Volume185, Issue1,Pages e12-e12
Skin melanoma usually arises on healthy-looking skin and this is called de novo melanoma (70% of melanoma). When melanoma arises on a pre-existing naevus (skin mole) it is called naevus-associated melanoma (NAM, 30% of melanoma). The differences between de novo and NAM are not clear because de novo melanoma are thicker tumours and there may have been a naevus component that was later replaced by tumour growth.
Atopic dermatitis, psychiatric disorders and medication use in childhood
doi : 10.1111/bjd.20451
Volume185, Issue1,Pages e13-e13
Atopic dermatitis (AD) is a very common skin condition, affecting around 15% of children. Symptoms, often beginning in early childhood, include itch and interrupted sleep. Children with AD have a higher risk of social isolation and reduced quality of life. Studies from adult patients have shown that depression and anxiety are related to AD. However, in children with AD, besides a connection to attention deficit hyperactivity disorder (ADHD), the occurrence of psychiatric disorders has not been thoroughly investigated.
Investigating the skin with sticky plastic discs
doi : 10.1111/bjd.20452
Volume185, Issue1,Pages e14-e14
A surprising amount of information about the skin can be obtained by studying the components of its outermost layer, the stratum corneum. For example, resident skin bacteria, proteins expressed in skin diseases such as eczema and even those associated with skin cancer can be investigated in this way.
Shielding behaviour in people with psoriasis or a joint condition during the COVID-19 pandemic differs by treatment type
doi : 10.1111/bjd.20453
Volume185, Issue1,Pages e15-e15
Public health measures such as social/physical distancing were introduced early in the pandemic to limit the spread of COVID-19. Stricter measures referred to as ‘shielding’ (not leaving home and minimizing all face-to-face contact) were recommended in groups of people at higher risk of severe infection. Many people taking drugs that affect the immune system to treat psoriasis or a joint condition (e.g. rheumatoid arthritis) were advised to reduce their risk of developing COVID-19 by shielding. We wanted to find out what factors influenced how much (or strictly) this advice was followed.
North American study of hand eczema in children
doi : 10.1111/bjd.20454
Volume185, Issue1,Pages e16-e16
Hand eczema (HE) is often triggered by something in contact with the skin, either an irritant (such as detergent) or a substance to which the person is allergic. Allergic contact dermatitis (ACD) is diagnosed by patch testing: substances that commonly cause allergy (allergens), placed in small chambers mounted on tape, are stuck on the upper back; after 48 hours the tape is removed and a patch of eczema at the site of a particular allergen reveals the culprit. Most research into ACD has been on adults and the cause is usually related to their work. Children are exposed to different substances so they might need to be patch tested with different allergens.
How long do patients with hidradenitis suppurativa gain benefit from biologic drugs?
doi : 10.1111/bjd.20455
Volume185, Issue1,Pages e17-e17
Hidradenitis suppurativa is a chronic skin disease in which persistent, painful, boil-like lesions develop especially in the armpits and groin. Treatment is often difficult, and patients with severe disease are eligible for so-called biologic therapy. The only registered biologic agent is adalimumab, a monoclonal antibody to the inflammatory mediator called tumour necrosis factor-? (TNF-?), although other biologic agents such as infliximab (another TNF-? antagonist) have been used. Unfortunately, these agents may lose their effect with time, sometimes because the patient develops antibodies to the drug, or side-effects may develop. Little is known about the long-term results of using these treatments in patients with hidradenitis suppurativa.
The role played by granulocyte colony-stimulating factor in hidradenitis suppurativa
doi : 10.1111/bjd.20456
Volume185, Issue1,Pages e18-e18
Hidradenitis suppurativa (HS) is a quite common, chronic skin disease that greatly impairs quality of life. Typically, the disease starts during early adulthood. Patients develop painful, tissue-destructive skin inflammation with abscesses and tunnels in body folds such as the armpit and groin.
??????????????????
doi : 10.1111/bjd.20457
Volume185, Issue1,Pages e19-e19
????????? (CERKL) ???????????????????, ?????????????, ??????????????; CERKL ?? (??) ?????????????????????, ??????????
???????????? (???) ??????
doi : 10.1111/bjd.20458
Volume185, Issue1,Pages e20-e20
???? (???) ???????? (??) ??????????????????, ???????????; ????????, ????????, ?????????????????????????????, ???????????????????????????????, ??????????????
????????????????
doi : 10.1111/bjd.20459
Volume185, Issue1,Pages e21-e21
???????????, ???????????????????? (???) ????? (???) ?????????????????????????????, ??????????????????
??????????????????????
doi : 10.1111/bjd.20460
Volume185, Issue1,Pages e22-e22
???????????, ???????????, ?????????????? 7/1000?????????????, ???????????????????????????????????????????????????????????????????????
????????????????????????????
doi : 10.1111/bjd.20461
Volume185, Issue1,Pages e23-e23
????????, ????????? (AD) ?????????????????????????????????????????????, ? AD ????????????????
???? T ?????????
doi : 10.1111/bjd.20462
Volume185, Issue1,Pages e24-e24
???????????, ?????????????????????????????? T ????, ?“T ??”??? T ????? (CTCL) ????????????, ???????????????? (MF) ? Sézary ??? (SS)?MF ???????, ? SS ???????? SS ????????????????????, ???????? MF ????????, ????, ??????
??????????????????????
doi : 10.1111/bjd.20463
Volume185, Issue1,Pages e25-e25
?????????????????????????????????, ??? 2-4 ?????????, ????????????? (?????) , ?????????????????????????, ????, ? 100 ????? 13 ?????????, ?? 50% ????????
??????????????????? HOME VII ????
doi : 10.1111/bjd.20464
Volume185, Issue1,Pages e26-e26
?????????? (HOME) ?????????, ?????????????????????????????????????????, ????????????????????????????????????
????????????????
doi : 10.1111/bjd.20465
Volume185, Issue1,Pages e27-e27
??????????????????, ???????? (70% ????) ??????? (???) ??????, ?????????? (NAM,30% ????) ??????? NAM ?????????, ?????????????, ??????????????????
????????????????
doi : 10.1111/bjd.20466
Volume185, Issue1,Pages e28-e28
????? (AD) ???????????, ?? 15% ?????????????????, ??????????AD ?????????????????????????????, ?????? AD ????? AD ???, ??????????? (ADHD) ???, ?????????????????
??????????
doi : 10.1111/bjd.20467
Volume185, Issue1,Pages e29-e29
?????????????, ????????????????, ??????????????????????????????, ????????????
? 2019 ????????? (COVID-19) ????, ???????????????????
doi : 10.1111/bjd.20468
Volume185, Issue1,Pages e30-e30
???????????/???????????, ??? COVID-19 ??????????????????, ??????“??” (???, ???????????) ?????????????????????????????????? (?????????) ??, ?????????? COVID-19 ?????????????????? (?????) ???????
??????????
doi : 10.1111/bjd.20469
Volume185, Issue1,Pages e31-e31
??? (HE) ???????????????, ?????????? (????) , ???????????????????? (ACD) ????????: ?????????? (???) ????????????, ?????????; 48 ???????, ??????????????????? ACD ??????????????, ???????????????????????, ??????????????????????
?????????????????????
doi : 10.1111/bjd.20470
Volume185, Issue1,Pages e32-e32
??????????????, ??????????????????, ??????????????????, ?????????????????????????????????, ????????????? a (TNF-?) ??????????, ????????????, ??????? (??? TNF-a ???) ?????, ???????????????????, ????????????, ???????????????????????????????????
????????????????????
doi : 10.1111/bjd.20471
Volume185, Issue1,Pages e33-e33
?????? (HS) ?????????????, ??????????????, ?????????????????????????????, ???????????????????????
